Drug Response Profiling (DRP) Registry Zurich for Hematological Malignancies

Summary

This study is a prospective, non-randomized feasibility study of drug response profiling (DRP) in pediatric blood cancers. Primary cancer cells are isolated from patients and screened ex vivo at single-cell resolution using automated fluorescence microscopy. Drug sensitivity fingerprints are integrated with genetic annotations to inform the treating physician about personalized treatment options. The study aims to determine the practicability of real-time drug response profiling and its actionability in identifying patient-specific cancer dependencies in refractory disease settings.

Eligibility

Inclusion Criteria:

* Pediatric and adult patients below the age of 40 years
* Diagnosis of hematological malignancy (primary, relapsed or refractory) including leukemia, myeloma or lymphoma
* Tumor material collected as part of routine diagnostics and willingness to donate tumor material for translational research
* Patient and/or guardian has signed the informed consent of the DRP registry or of a clinical trial which includes DRP as add-on research.

Exclusion Criteria:

* Missing informed consent for the registry or of a clinical trial which includes DRP as add-on research

Conditions2

Browse More Trials